Skip to main content
. Author manuscript; available in PMC: 2015 Mar 1.
Published in final edited form as: J Burn Care Res. 2014 Mar-Apr;35(2):e83–e92. doi: 10.1097/BCR.0b013e31828a8d6e

Fig. 4. Topical p38MAPK inhibition attenuates acute dermal proinflammatory cytokine expression.

Fig. 4

Skin samples, harvested at 12 or 24 hours post-injury, were homogenized and supernatants were processed by ELISA for IL-6 (A), MIP-2 (B) and IL-1β (C) detection. Topical treatment with a p38MAPK inhibitor resulted in significant inhibition of dermal proinflammatory cytokine expression versus untreated burn control with both immediate and delayed (4h post-injury) application. Data presented as mean ± 95% confidence interval. *p < 0.001, **p< 0.03, ANOVA, n= 15 per group (5 animals/group × 3 experiments).